Novartis and Pan-Canadian Finalize Deal to Make Cosentyx Accessible for HS Patients

Novartis and Pan-Canadian’s Partnership has Finalized Negotiations

Announcement

Novartis Pharmaceuticals Canada Inc. finally confirms its partnership with Pan-Canadian Pharmaceutical by settling down with an effective negotiation on (Pcpa) public reimbursement of Cosentyx (secukinumab) for the treatment of adults with extreme to normal hidradenitis suppurativa (HS), which is a painful, chronically inflammatory skin disease. According to the negotiation, Cosentyx is listed in Quebec, which will be the primary province to enable public reimbursement for Cosentyx in HS. Novartis stands by its commitment to its ongoing partnership with provincial public drug programs in Canada to deliver in time reimbursement and access to eligible patients globally.

This is a conclusion to the healthcare market as it will be providing a solution to the extreme skin condition. The companies will further introduce an effective medication for this condition with their advanced skills. The growth rate of the skin care market is fueling due to its heavy demand for healthy and infection-free skin. Scientifically, companies' respective expertise, dermatologists, and suitable healthcare professionals can incorporate an effective solution to meet the needs of HS individuals. With the end of this negotiation, the companies will be able to focus more on targeting the HS infection and come up with advanced medication for this infection. The clinical trials and study will prove the potential of the medication, which has yet to be discovered.

Views and Statements

Founder of Hidradenitis and Me support group, Latoya Palmer, said, “Most of the time, people with HS feel that their condition is not noticeable in the healthcare system. Being an Individual living with HS, the current development and steps are giving hope to individuals like us. This makes me and others feel validated with this support, which is required the most.”

Canadian and US board-certified dermatologists, Dr. Susan Poelman said, “Individuals suffering from severe or moderate HS condition can be affected in their daily life routine and may also impact their emotional state. The completion of the Pcpa negotiation for Cosentyx is a valuable step that will extend possibilities for patients with limited options for the treatment.”

Country president of Novartis pharmaceuticals Canada Inc., Mark Vineis, said, “The conclusion of pcpa negotiation for Cosentyx in HS was a required step to discover therapies rooted in strong science and real patient need. Our company is highly committed to working with stakeholders in the healthcare system to support eligible patients by helping them with HS. The public access to innovative treatment options is a major contribution to individuals.”